Abstract
Okinawa Prefecture, located in the subtropics, is an area of endemic adult T-cell leukemia–lymphoma (ATL) in Japan. We retrospectively analyzed 659 patients with aggressive ATL in seven institutions in Okinawa between 2002 and 2011. The median patient age was 68 years. More patients were aged ≥90 years (2.6 %), in this study, than in a nationwide survey (<1 %). The median survival time (MST) of the entire cohort was 6.5 months. Of the 217 patients who had a clinical status similar to that stated in the eligibility criteria of JCOG9801 (a randomized phase III study comparing VCAP-AMP-VECP with CHOP-14), 147 who received the CHOP regimen had a poorer MST than those in the CHOP-14 arm of JCOG9801 (8 vs 11 months). The prevalence of strongyloidiasis in the ATL patients was much higher (12.4 %) than in the historical cohort who visited the University of the Ryukyus Hospital (3.4 %). Furthermore, strongyloidiasis may be associated with ATL-related deaths. These findings suggest that, compared with other areas in Japan, in Okinawa, the proportion of patients aged ≥90 years with clinical features of aggressive ATL is higher, outcomes are poorer, and the disease is associated with a higher prevalence of strongyloidiasis.
Similar content being viewed by others
References
Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic featuresof 16 cases. Blood. 1977;50:481–92.
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415–9.
Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA. 1981;78:6476–80.
Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal cord leukocytes and human leukaemic T cells. Nature. 1981;294:770–1.
Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031–5.
Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79:428–37.
Shimoyama M. Chemotherpy of ATL. In: Takatsuki K, editor. Adult T-cell leukemia. United Kingdom: Oxford University Press, Oxford; 1994. p. 221–37.
Tobinai K, Watanabe T. Adult T-cell leukemia–lymphoma. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MCB, editors. Clinical oncology, 3rd ed. Philadelphia: Elsevier Churchill Livingstone; 2004. p. 3109–30.
Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, Takatsuki K, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin’s lymphoma treated with VEPA or VEPA-M. J Clin Oncol. 1988;6:128–41.
Lymphoma Study Group. Major prognostic factors of patients with adult T-cell leukemia–lymphoma: a cooperative study—Lymphoma Study Group (1984–1987). Leuk Res. 1991;15:81–90.
Tobinai K, Shimoyama M, Minato K, Shirakawa S, Kobayashi T, Hotta T. Japan Clinical Oncology Group phase II trial of second-generation “LSG4 protocol” in aggressive T- and B-lymphoma: a new predictive model for T- and B-lymphoma. Proc Am Soc Clin Oncol. 1994;13:378.
Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, et al. Lymphoma Study Group of the Japan Clinical Oncology Group. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia–lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77:164–70.
Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375–82.
Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Japan Clinical Oncology Group Study JCOG9801, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia–lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458–64.
Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369–76.
Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia–lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734–41.
Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcome after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141–8.
Tajima K, The T- and B-cell Malignancy Study Group. The 4th nationwide study of adult T-cell leukemia/lymphoma (ATL in Japan): estimates of risk of ATL and its geographical and clinical features. Int J Cancer. 1990;45:237–43.
Yamada Y, Atogami S, Hasegawa H, Kamihira S, Sohda M, Satake M, Yamaguchi K. Nationwide survey of adult T-cell leukemia/lymphoma (ATL) in Japan. Rinshoketsueki. 2011;52:1765–71.
Hirata T, Nakamura H, Kinjo N, Hokama A, Kinjo F, Yamane N, Fujita J. Prevalence of blastocystis hominis and Strongyloides stercoralis infection in Okinawa, Japan. Parasito Res. 2007;101:1717–9.
Makiyama J, Imaizumi Y, Tsushima H, Taniguchi H, Moriwaki Y, Sawayama Y, et al. Treatment outcome of elderly patients with aggressive adult T-cell leukemia–lymphoma: Nagasaki University Hospital experience. Int J Hematol. 2014;100:464–72.
Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone of in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia–lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672–82.
O’Doherty MJ, Van de Pette JE, Numan TO. Recurrent Strongyloides stercoralis infection in a patient with T-cell lymphoma–leukemia (letter). Lancet. 1984;1(8381):858.
Nakada K, Yamaguchi K, Furugen S, Nakasone T, Oshiro Y, Hinuma Y, et al. Monoclonal integration of HTLV-1 proviral DNA in patients with strongyloidiasis. Int J Cancer. 1987;40:145–8.
Gotuzzo E, Terashima A, Alvarez H, Tello R, Infante R, Watts DM, Freedman DO. Strongyloides stercoralis hyperinfection associated with human T-cell lymphotropic virus type-I infection in Peru. Am J Trop Med Hyg. 1999;60:146–9.
Newton RC, Limpuangthip P, Greenberg S, Gam A, Neva FA. Strongyloides stercoralis hyperinfection in a carrier of HTLV-1 virus with evidence of selective immunosuppression. Am J Med. 1992;92:202–8.
Phelps KR. Strongyloides hyperinfection in patients coinfected with HTLV-1 and S. stercoralis. Am J Med. 1993;94:447–9.
Acknowledgments
This work was supported by a grant from Okinawa Prefecture, Japan (grant to T.F. and T.T.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no potential conflict of interest.
About this article
Cite this article
Nishi, Y., Fukushima, T., Nomura, S. et al. Characterization of patients with aggressive adult T-cell leukemia–lymphoma in Okinawa, Japan: a retrospective analysis of a large cohort. Int J Hematol 104, 468–475 (2016). https://doi.org/10.1007/s12185-016-2042-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-016-2042-y